Contact Us

Byetta Pancreatic, Liver, Thyroid Cancer
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Byetta Pancreatic, Liver, Thyroid Cancer


Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to Friend Print Page

Byetta Use May Increase Risk of Pancreatic, Liver or Thyroid Cancer Lawsuit

Byetta Side Effects Include Pancreatic Cancer, Liver Cancer, Thyroid Cancer. Treats Type 2 Diabetes

Byetta, an injectable drug used to treat Type 2 Diabetes, may be associated with an increased risk of pancreatic cancer, liver cancer or thyroid cancer. Byetta has been seen to cause life-threatening pancreatitis in some patients, a condition that if it becomes chronic, can lead to pancreatic cancer. In 2010, the U.S. Food & Drug Administration (FDA) reported that drugs in the same class as Byetta could be linked to an increased risk of thyroid tumors.

If you or a loved one took Byetta and were diagnosed with pancreatic cancer, liver cancer or thyroid cancer, you may be entitled to compensation. The lawyers at Parker Waichman LLP are offering free lawsuit evaluations to anyone who may have developed pancreatic cancer, liver cancer or thyroid cancer, because of this defective drug. To learn how our Byetta cancer lawyers can help you, please contact us today

Byetta and Pancreatic Cancer

Byetta belongs to a class of drugs known as GLP-1 analogs. These drugs act by enhancing the activity of a hormone in the gastro-intestinal tract called glucagon-like-peptide-1 (GLP-1), which results in lower blood sugar levels.

Byetta has been linked to life-threatening pancreatic problems, including hemorrhagic and necrotizing pancreatitis. In 2008, the FDA said it had received more than 30 reports of acute pancreatitis in Byetta users, as well as two deaths and four hospitalizations for pancreatic problems. In 2009, the FDA directed the maker of Byetta to conduct six post-marketing studies to help further define the mechanism, incidence, and risk factors for the development of acute pancreatitis, including hemorrhagic and necrotizing pancreatitis, associated with the use of Byetta, as well as to explore a potential signal of a serious risk of thyroid cancer and pancreatic cancer.

Chronic pancreatitis is often a precursor to pancreatic cancer, one of the deadliest types of cancer. For that reason Byetta patients need to be aware of the signs and symptoms of pancreatitis. They must seek medical attention immediately should they experience any symptoms.

Possible symptoms of Byetta pancreatitis include:

  • Abdominal pain
  • Vomiting
  • Fever
  • Nausea
  • Rapid heartbeat
  • Swollen, tender abdomen
  • Changes in bowel movements

Byetta and Thyroid Cancer

In 2010, an FDA advisory panel revealed that another drug in the same class as Byetta had been seen to cause thyroid tumors in laboratory animals. The FDA expressed concern that all extended-release Diabetes drugs belonging to that family may be linked to thyroid tumors. As a result, the agency said strict label warnings may be necessary to alert users of these drugs - including Byetta - about the potential cancer risk and the possibility of thyroid tumors. Victoza, the GLP analog that prompted this concern, already bears a Black Box warning about a possible association with thyroid cancer.

Amylin Pharmaceuticals, which manufactures and distributes the drug jointly with Eli Lilly, tried to downplay the Byetta pancreatic cancer, liver cancer and thyroid cancer risks. It pointed out that Victoza and Byetta are different molecules, and indicated that there was no evidence of any link between Byetta and thyroid cancer. However, following the FDA report company officials conceded that cancer concerns, while not proven, cannot be ruled out as a side effect of Byetta. The company added that a statistically significant increase in thyroid cancers was seen in female rats given doses significantly higher than what is normal.

Help for Byetta pancreatic cancer, liver cancer or thyroid cancer Victims

If you suffer from pancreatic cancer, liver cancer or thyroid cancer, and you took Byetta, you may have valuable legal rights. To learn how our Byetta cancer lawyers can help you, please fill out our online form or call 1-800-YOURLAWYER (1-800-968-7529) today.

Byetta Pancreatic, Liver, Thyroid CancerRSS Feed

FDA Probes Pancreatic Cancer Risk with Diabetes Drugs Januvia, Byetta and Victoza

Mar 15, 2013
The U.S. Food and Drug Administration (FDA) is examining new evidence that suggests a group of recently approved diabetes drugs, including Januvia, Byetta and Victoza may have a link to pancreatic cancer. In a March 14 Drug Safety Communication, the agency said samples of pancreatic tissue taken from a number of patients showed inflammation and cellular changes that often precede cancer. The tissue samples came from diabetes patients who were taking the new medications, after they died from...

Byetta, Januvia Cancer Risks Debated

Sep 21, 2011 | Parker Waichman LLP
The uncertainty surrounding type 2 diabetes drugs like  Byetta and Januvia have prompted calls for more studies of glucagon-like peptide 1 (GLP-1) therapies.  A recent study has tied Byetta and Januvia to a possible increased risk of pancreatic cancer, but other researchers, along with the drug's manufacturers.GLP-1 therapies mimic a hormone called GLP-1 to stimulate natural insulin production in diabetics.  In addition to Byetta and Januvia, Novo Nordisk's Victoza is also in...

Study Find Januvia, Byetta Associated with Increased Risk of Pancreatitis, Pancreatic Cancer

Sep 19, 2011 | Parker Waichman LLP
Diabetes drugs that lower blood sugar by promoting the action of a gut hormone called glucagon-like peptide 1 (GLP-1) may increase the risks of both pancreatitis and pancreatic cancer, according to a new study published in the journal Gastroenterology.  The study found that Januvia and Byetta, both type 2 diabetes medications, increased the risk of pancreatitis by 6-fold.  Pancreatitis is a known risk-factor for pancreatic cancer.According to a report from EMaxHealth, animal studies...

Doctors Reminded of Victoza Thyroid Tumor, Pancreatitis Risks

Jun 14, 2011 | Parker Waichman LLP
It seems many doctors are unaware of the serious side effects that may be associated with the Type II Diabetes drug Victoza.  As a result, Novo Nordisk has sent a letter to doctors reminding them that Victoza may be associated with thyroid tumors and acute pancreatitis.Victoza is very similar to Byetta.  Both are injectables, and both act on glucagon-like-peptide-1 (GLP-1), a hormone in the digestive tract that impacts glucose levels.According to the Novo Nordisk Victoza letter,...

Victoza Report Raises Byetta Safety Questions

Jun 7, 2011 | Parker Waichman LLP
A new report from the Institute for Safe Medicine Practices (ISMP) may raise safety concerns about a new generation of diabetes drugs, including Byetta.  While the group’s new QuarterWatch report discusses another drug called Victoza and pancreatitis, the ISMP raises concerns that similar diabetes medications may also pose an elevated risk of pancreatitis.Both Byetta and Victoza are injectable medications that act on glucagon-like-peptide-1 (GLP-1), a hormone in the digestive tract...

More Byetta Pancreatic, Liver, Thyroid Cancer News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5